نتائج البحث

Comparative Efficacy and Safety Between Deferiprone and Deferasirox with Special Reference to Serum Ferritin Level and Cardiac Function in Bengali β-Thalassemia Major Children.

• Authors : Tripathy I; Department of Paediatric Medicine, Nilratan Sircar Medical College and Hospital, Kolkata, West Bengal, India.; Panja A

Subjects: Deferasirox*/Deferasirox*/Deferasirox*/adverse effects ; Deferasirox*/Deferasirox*/Deferasirox*/therapeutic use ; Deferiprone*/Deferiprone*/Deferiprone*/adverse effects

• Source: Hemoglobin [Hemoglobin] 2021 Sep; Vol. 45 (5), pp. 296-302. Date of Electronic Publication: 2021 Nov 10.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Efficacy and Safety of a Dispersible Tablet of GPO-Deferasirox Monotherapy among Children with Transfusion-Dependent Thalassemia and Iron Overload.

• Authors : Chuansumrit A; Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.; Songdej D

Subjects: Iron Overload*/Iron Overload*/Iron Overload*/drug therapy ; Iron Overload*/Iron Overload*/Iron Overload*/etiology ; Thalassemia*/Thalassemia*/Thalassemia*/drug therapy

• Source: Hemoglobin [Hemoglobin] 2024 Jan; Vol. 48 (1), pp. 47-55. Date of Electronic Publication: 2024 Feb 18.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Iron Chelators, Such as Deferasirox, When Combined With Hydroxyurea, Provide an Additional Benefit of Iron Chelation in Patients Receiving Chronic Transfusion Therapy.

• Authors : Manganas K; Thalassaemia and Sickle Cell Department, Hippokration General Hospital, Athens, Greece.; Delicou S

Subjects: Anemia, Sickle Cell*/Anemia, Sickle Cell*/Anemia, Sickle Cell*/complications ; Anemia, Sickle Cell*/Anemia, Sickle Cell*/Anemia, Sickle Cell*/therapy ; Iron Chelating Agents*/Iron Chelating Agents*/Iron Chelating Agents*/therapeutic use

• Source: Hemoglobin [Hemoglobin] 2022 Mar; Vol. 46 (2), pp. 114-117. Date of Electronic Publication: 2022 Sep 07.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Perforated Duodenal Ulcer Associated with Deferasirox in a Child with β-Thalassemia Major.

• Authors : Zahra A; Pediatric Hematology Unit, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait.; Ragab A

Subjects: Duodenal Ulcer*/Duodenal Ulcer*/Duodenal Ulcer*/complications ; Duodenal Ulcer*/Duodenal Ulcer*/Duodenal Ulcer*/drug therapy ; Iron Overload*/Iron Overload*/Iron Overload*/diagnosis

• Source: Hemoglobin [Hemoglobin] 2021 Sep; Vol. 45 (5), pp. 335-337. Date of Electronic Publication: 2022 Jan 03.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

A Study to Assess and Improve Adherence to Iron Chelation Therapy in Transfusion-Dependent Thalassemia Patients.

• Authors : Theppornpitak K; Department of Pediatrics, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.; Trakarnsanga B

Subjects: Chelation Therapy* ; Iron Chelating Agents*/Iron Chelating Agents*/Iron Chelating Agents*/therapeutic use ; Iron Overload*/Iron Overload*/Iron Overload*/drug therapy

• Source: Hemoglobin [Hemoglobin] 2021 May; Vol. 45 (3), pp. 171-174. Date of Electronic Publication: 2021 Jun 08.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran.

• Authors : Zardkhoni SZ; Department of Pediatrics, Yasuj University of Medical Sciences, Yasuj, Iran.; Moghaddam AG

Subjects: beta-Thalassemia*/beta-Thalassemia*/beta-Thalassemia*/drug therapy ; beta-Thalassemia*/beta-Thalassemia*/beta-Thalassemia*/epidemiology ; Iron Overload*

• Source: Hemoglobin [Hemoglobin] 2021 Mar; Vol. 45 (2), pp. 103-106. Date of Electronic Publication: 2021 Apr 26.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Five Years of Deferasirox Therapy for Cardiac Iron in β -Thalassemia Major.

• Authors : Vlachaki, Efthymia¹ (AUTHOR) ; Agapidou, Alexandra¹ (AUTHOR); Spanos, Georgios² (AUTHOR)

• Source: Hemoglobin. Oct2015, Vol. 39 Issue 5, p299-304. 6p.

تفاصيل العنوان

Deferasirox: An Update.

• Authors : Porter, John B.¹ (AUTHOR)

• Source: Hemoglobin. Feb2009 Supplement 1, Vol. 33, pS70-S75. 6p.

تفاصيل العنوان

Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.

• Authors : Karimi M; a Hematology Research Centre, Shiraz University of Medical Sciences , Shiraz , Iran.; Arandi N

Subjects: Benzoates/Benzoates/Benzoates/*therapeutic use ; Iron Chelating Agents/Iron Chelating Agents/Iron Chelating Agents/*therapeutic use ; Iron Overload/Iron Overload/Iron Overload/*drug therapy

• Source: Hemoglobin [Hemoglobin] 2015; Vol. 39 (5), pp. 327-9. Date of Electronic Publication: 2015 Jun 26.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.

• Authors : Tanphaichitr A; Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University , Bangkok , Thailand .; Kusuwan T

Subjects: Transfusion Reaction*; Chelation Therapy/Chelation Therapy/Chelation Therapy/*adverse effects ; Hearing Loss, Sensorineural/Hearing Loss, Sensorineural/Hearing Loss, Sensorineural/*chemically induced

• Source: Hemoglobin [Hemoglobin] 2014; Vol. 38 (5), pp. 345-50. Date of Electronic Publication: 2014 Jul 22.Publisher: Informa Healthcare Country of Publication: England NLM ID: 7705865 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان